Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexaria Bioscience Corp

1.32
-0.1200-8.33%
Post-market: 1.320.00000.00%19:11 EDT
Volume:26.73K
Turnover:36.61K
Market Cap:23.17M
PE:-2.58
High:1.41
Open:1.35
Low:1.32
Close:1.44
Loading ...

Company Profile

Company Name:
Lexaria Bioscience Corp
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
7
Office Location:
740 McCurdy Road,Suite 100,Kelowna,British Columbia,Canada
Zip Code:
V1X 2P7
Fax:
- -
Introduction:
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and various cannabinoids. The company's DehydraTECH technology evaluates for a variety of therapeutic indications, including hypertension, heart disease, dementia, and diabetes. It is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna, Canada.

Directors

Name
Position
Christopher Bunka
Chairman and Director
John Docherty
President and Director
Al Reese Jr.
Director
Catherine Turkel
Director
Nicholas Baxter
Director
Ted McKechnie
Director

Shareholders

Name
Position
Richard Christopher
Chief Executive Officer
Michael Shankman
Chief Financial Officer
John Docherty
President and Director